[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO992315L - Benzotiazo and related heterocyclic group-containing cysteine and serine protease inhibitors - Google Patents

Benzotiazo and related heterocyclic group-containing cysteine and serine protease inhibitors

Info

Publication number
NO992315L
NO992315L NO992315A NO992315A NO992315L NO 992315 L NO992315 L NO 992315L NO 992315 A NO992315 A NO 992315A NO 992315 A NO992315 A NO 992315A NO 992315 L NO992315 L NO 992315L
Authority
NO
Norway
Prior art keywords
benzotiazo
heterocyclic group
protease inhibitors
serine protease
related heterocyclic
Prior art date
Application number
NO992315A
Other languages
Norwegian (no)
Other versions
NO992315D0 (en
Inventor
Ron Bihovsky
Gregory J Wells
Ming Tao
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/968,035 external-priority patent/US5952328A/en
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO992315D0 publication Critical patent/NO992315D0/en
Publication of NO992315L publication Critical patent/NO992315L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6544—Six-membered rings
    • C07F9/6547—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det er beskrevet en oppfinnelse rettet mot nye bensotiazo og beslektede heterosykliske gruppeinneholdende inhibitorer av cystein eller serinproteaser. Fremgangsmåte for anvendelse av disse er også beskrevet.An invention is described for novel benzotiazo and related heterocyclic group-containing inhibitors of cysteine or serine proteases. Procedures for using them are also described.

NO992315A 1996-11-13 1999-05-12 Benzotiazo and related heterocyclic group-containing cysteine and serine protease inhibitors NO992315L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3052696P 1996-11-13 1996-11-13
US08/968,035 US5952328A (en) 1997-11-12 1997-11-12 Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors
PCT/US1997/020782 WO1998021186A1 (en) 1996-11-13 1997-11-13 Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors

Publications (2)

Publication Number Publication Date
NO992315D0 NO992315D0 (en) 1999-05-12
NO992315L true NO992315L (en) 1999-06-11

Family

ID=26706137

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992315A NO992315L (en) 1996-11-13 1999-05-12 Benzotiazo and related heterocyclic group-containing cysteine and serine protease inhibitors

Country Status (6)

Country Link
EP (1) EP0938477A4 (en)
JP (1) JP2002514192A (en)
AU (1) AU7179598A (en)
CA (1) CA2271116A1 (en)
NO (1) NO992315L (en)
WO (1) WO1998021186A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2286660A1 (en) * 1997-04-16 1998-10-22 Arqule, Inc. Synthesis and use of .alpha.-ketoamide derivatives and arrays
US6143931A (en) * 1997-04-16 2000-11-07 Arqule, Inc. Synthesis and use of α-ketoamide derivatives and arrays
US6150378A (en) * 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
JP2002503657A (en) 1998-02-11 2002-02-05 デュポン ファーマシューティカルズ カンパニー Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
EP1068191A1 (en) * 1998-03-31 2001-01-17 Warner-Lambert Company Llc Benzoxazinones/benzothiazinones as serine protease inhibitors
US7704958B1 (en) 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
FR2818641B1 (en) * 2000-12-21 2004-03-05 Servier Lab NOVEL 1,1-DIOXO-2H-1,2-BENZOTHIAZINE 3-CARBOXAMIDES DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES2622522T3 (en) 2003-08-26 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Inhibitors of serine protease activity and its use in methods and compositions for the treatment of bacterial infections
BRPI0508183B8 (en) 2004-04-02 2021-05-25 Prana Biotechnology Ltd neurologically active compounds, their uses, pharmaceutical or veterinary composition and processes for their preparation
WO2007011820A2 (en) 2005-07-15 2007-01-25 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2009015917A2 (en) 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
US8236798B2 (en) * 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
EP3426674A4 (en) 2016-03-09 2019-08-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
EP3481835A4 (en) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
JP2019533007A (en) * 2016-09-13 2019-11-14 ハプロゲン・ゲーエムベーハー Antiviral compounds
PE20191153A1 (en) 2016-09-28 2019-09-05 Blade Therapeutics Inc CALPAINE MODULATORS AND THERAPEUTIC USES OF THE SAME
GB201713962D0 (en) * 2017-08-31 2017-10-18 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
LT3986890T (en) 2019-06-18 2023-12-11 Pfizer Inc. Benzisoxazole sulfonamide derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960854A (en) * 1972-03-20 1976-06-01 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
JPS58225076A (en) * 1982-06-23 1983-12-27 Mitsui Toatsu Chem Inc Benzothiazinecarboxyamide derivative and pharmaceutical composition containing the same
US4585793A (en) * 1983-05-09 1986-04-29 Georgia Tech Research Institute Thioester inhibitors of serine proteases
GB2146026A (en) * 1983-09-07 1985-04-11 Tanabe Seiyaku Co Peptides and process for preparing the same
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
JPH0629271B2 (en) * 1988-03-09 1994-04-20 株式会社日本ハイポックス Benzothiazine-1,1-dioxide derivative and pharmaceutical composition containing the same
US5384411A (en) * 1991-06-20 1995-01-24 Hewlett-Packard Company Immobilization of PH-sensitive dyes to solid supports
DK0590455T3 (en) * 1992-09-28 2001-01-22 Hoechst Ag Antiarrhythmic and cardioprotective substituted 1 (2H) -isoquinolines, method for their preparation, drug containing
DE69630701T2 (en) * 1995-07-17 2004-08-19 Cephalon, Inc. CYSTEIN AND SERINE PROTEASES INHIBITORS CONTAINING PHOSPHORUS

Also Published As

Publication number Publication date
AU7179598A (en) 1998-06-03
WO1998021186A1 (en) 1998-05-22
NO992315D0 (en) 1999-05-12
EP0938477A1 (en) 1999-09-01
EP0938477A4 (en) 1999-12-29
JP2002514192A (en) 2002-05-14
CA2271116A1 (en) 1998-05-22

Similar Documents

Publication Publication Date Title
NO992315L (en) Benzotiazo and related heterocyclic group-containing cysteine and serine protease inhibitors
DE69637307D1 (en) CYSTEIN AND SERINE PROTEASE INHIBITORS DERIVED FROM D-AMINO ACIDS
ATE335485T1 (en) QUINOLINE-CONTAINING ALPHA-KETOAMIDE BASED CYSTEIN AND SERINE PROTEASE INHIBITORS
DK0871454T3 (en) Phosphorus-containing inhibitors of cysteine and serine protease
NO990548L (en) Inhibitors of cysteine protease
EE9900161A (en) Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
DK204290D0 (en) ENZYMATIC DETERGENT COMPOSITION AND PROCEDURE FOR ENZYME STABILIZATION
UY27972A1 (en) HIDANTOINE DERIVATIVES
TR199801794T2 (en) How long has it been?
MX9703564A (en) Multicatalytic protease inhibitors.
DK0691988T3 (en) Inhibitor of stem cell proliferation and applications thereof
DK1084146T3 (en) Hybrid protein for inhibiting the degranulation of mastocytes and their use
HK1025511A1 (en) Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
DE69705838D1 (en) SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMS
NO983688D0 (en) Serine protease inhibitors
NO964416D0 (en) Methods for Preparing Effective Recombinant Serine Protease Inhibitors and Uses of These Inhibitors
TR199902751T2 (en) Protease inhibitors.
DK0784677T3 (en) Inhibitor of stem cell proliferation and applications thereof
KR960701085A (en) Peptide BORONIC ACID DERIVATIVES HAVING PROTEASE INHIBITING ACTIVITY
DE69730871D1 (en) SERINE PROTEASE INHIBITORS
DK0886647T3 (en) serine protease inhibitors
NO20002848L (en) New connections
DE69941152D1 (en) HYDROXAMATE-CONTAINING INHIBITORS OF CYSTEIN AND SERINE PROTEASES
ATE211719T1 (en) INJECTION CEMENT CONTAINING CORROSION INHIBITORS
MX9805948A (en) Substrates and inhibitors for cysteine protease ich-1

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application